Survival in Chemotherapy Refractory Metastatic Colorectal Cancer
Author Information
Author(s): Hsiao Kai-Yuan, Chen Hsin-Pao, Rau Kun-Ming, Liu Kuang-Wen, Shia Ben-Chang, Chang Wei-Shan, Liang Hao-Yun, Hsieh Meng-Che
Primary Institution: Fu Jen Catholic University, New Taipei City, Taiwan
Hypothesis
This study aimed to investigate the association between sidedness and survival among chemotherapy refractory patients with metastatic colorectal cancer treated with TAS-102 or regorafenib.
Conclusion
TAS-102 first provided a better survival benefit in chemotherapy refractory patients with metastatic colorectal cancer across all sidedness.
Supporting Evidence
- Overall survival was significantly longer in the TAS-102 group compared to the regorafenib group.
- Median overall survival was 9.1 months for TAS-102 and 7.0 months for regorafenib.
- Treatment sequence significantly affected time-to-treatment failure and overall survival.
- Patients with left-side colon cancer showed better survival outcomes with TAS-102.
- Subgroup analysis indicated significant differences in survival based on treatment sequence.
Takeaway
Doctors studied how the side of the colon cancer affects survival in patients who didn't respond to other treatments. They found that starting with one specific medicine helped patients live longer.
Methodology
This was a retrospective nationwide population-based study using data from the National Health Insurance Research Database and Taiwan Cancer Registry, with patients matched by propensity score.
Potential Biases
Selection bias may have occurred due to the non-randomized nature of treatment assignment.
Limitations
The study is retrospective, which may introduce bias, and the dosing schedules of treatments were not available.
Participant Demographics
The median age was 63 years, with a predominance of male participants (55%). Approximately 80% had left-side colon cancer.
Statistical Information
P-Value
0.008
Confidence Interval
0.678-0.957
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website